Literature DB >> 21498089

Which comorbidity classification best fits elderly candidates for radical prostatectomy?

Michael Froehner1, Caroline Hentschel, Rainer Koch, Rainer J Litz, Oliver W Hakenberg, Manfred P Wirth.   

Abstract

OBJECTIVES: Comorbidity assessment may assist in the treatment choice for elderly men with prostate cancer. There is, however, no consensus on the best comorbidity classification for this purpose. In this study, we used a heuristic approach to identify an optimal comorbidity classification in elderly men selected for radical prostatectomy. METHODS AND MATERIALS: A total of 1,106 men aged 65 years or older who underwent radical prostatectomy for clinically localized prostate cancer were stratified by 11 3-sided comorbidity classifications. Overall survival was the study endpoint. The comorbidity classifications were evaluated considering 4 statistical (height of hazard ratios and P values, survival difference between high and low risk patients, dose-response relationship) and 4 clinical demands (survival rates in low and high risk group, balance of the proportion of the risk groups). The 3 best classifications in each category received 3, 2, or 1 point. After adding all points, the classification with the highest score was considered best.
RESULTS: With one exception, all comorbidity classifications were significant predictors of overall survival. Comparing the highest with the lowest risk group, the hazard ratios ranged between 1.67 and 3.93. Concerning the fulfillment of clinical and statistical demands, the American Society of Anesthesiologists (ASA) physical status classification and 1 derivative of it that included further more clearly defined diseases were the most promising candidates.
CONCLUSIONS: Stratifying candidates for radical prostatectomy according to their mortality risk using the ASA classification as a backbone supplemented by a list of more clearly defined concomitant diseases could be useful in clinical practice and outcome studies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21498089     DOI: 10.1016/j.urolonc.2011.03.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  4 in total

1.  [Age and comorbidity in early prostate cancer].

Authors:  M Fröhner; M P Wirth
Journal:  Urologe A       Date:  2012-10       Impact factor: 0.639

2.  Long term results of HDR brachytherapy in men older than 75 with localized carcinoma of the prostate.

Authors:  Renata Soumarová; Luboš Homola; Hana Perková
Journal:  Rep Pract Oncol Radiother       Date:  2012-10-22

3.  Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study.

Authors:  Ho Won Kang; Sung Pil Seo; Won Tae Kim; Yong June Kim; Seok Joong Yun; Sang Cheol Lee; Young Deuk Choi; Yun Sok Ha; Tae Hwan Kim; Tae Gyun Kwon; Seok Soo Byun; Seong Uk Jeh; Wun Jae Kim
Journal:  J Korean Med Sci       Date:  2017-02       Impact factor: 2.153

4.  Evaluation of comorbidity indices in determining the most suitable candidates for uro-oncological surgeries in elderly men.

Authors:  Ismail Selvi; Ali Ihsan Arik; Numan Baydilli; Mehmet Sinan Basay; Halil Basar
Journal:  Cent European J Urol       Date:  2021-03-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.